In a long-debated move, the NIH will no longer characterize basic experimental studies involving humans as clinical trials.

The emergence of AI and biosensors offers a chance to address inefficiencies in drug development.

The guidance encourages the use of Bayesian statistics in drug trials. Instead of starting from scratch and only adding new ...

Faculty in this hub lead the design, coordination, and analysis of clinical trials for cancer treatment, survivorship, vaccine efficacy, infectious disease prevention and treatment, and cancer ...

The department has created an internal working group to look at “developing a singular database where we can capture veteran enrollment data in real time,” according to Liza Catucci, VA’s acting ...

In the last decade, the volume of clinical trial data has surged, presenting unprecedented challenges for sponsors and contract research organizations (CROs). The task of collecting, cleaning, ...

Three early-career scientists who recently completed their PhDs at Northwestern have been named Chicago Biomedical Consortium ...

Using KRIs or SDM, sponsors can detect a variety of emerging risks, including inadequate adverse-event reporting, protocol deviations or delays in data entry. Importantly, these risks can be flagged ...

Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...

A research team led by the Department of Medicine, under the School of Clinical Medicine, LKS Faculty of Medicine of the ...

On this episode of "The Top Line," Fierce Biotech's James Waldron and Fierce Pharma's Fraiser Kansteiner discuss the clinical trial failures that stood out in 2025 and what they suggest about the ...